Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
- EMERALD Chief Investigator Prof. Jonathan Fallowfield will present the poster on study design
- EMERALD is a multicentre Phase I/II study evaluating Resolution’s Regenerative Macrophage Therapy RTX001 in patients with end-stage liver disease taking place in the UK and Spain
- First patient dosed successfully, and safety cleared at Royal Infirmary of Edinburgh
Edinburgh and London, UK, 7 October 2025 – Resolution Therapeutics Ltd (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announces the presentation of the study design for its EMERALD Phase I/II clinical trial at the British Association for the Study of the Liver (BASL) annual meeting 2025. The conference is taking place in Belfast, Northern Ireland, between 7-10 October 2025.
